Drug recall · February 9, 2022
Ephedrine Plus recall
Why: cGMP deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ephedrine Plus (Ephedrine HCl 25mg, Guaifenesin 200mg) tablets, 24-count bottles, Marketed by: DMD Pharmaceuticals A Division of Dickery Consumer Products, Inc. Noblesville, IN 46060, NDC 65193-320-24
- Lots / codes
Lot#: 18M063, Exp. Date 01/2022; 19G076, Exp. Date 09/2022
- Quantity
- 301,842 bottles
- Company
- Ultra Seal Corporation, New Paltz, NY
- Distribution
- Nationwide within the United States
- Initiated
- January 24, 2022 · Voluntary: Firm initiated
- Classified
- January 31, 2022
- Reported
- February 9, 2022
- Ended
- October 16, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Guaifenesin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.